↓ Skip to main content

Adjuvant Therapy Trials

Overview of attention for article published in Cancer Journal, May 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Adjuvant Therapy Trials
Published in
Cancer Journal, May 2016
DOI 10.1097/ppo.0000000000000188
Pubmed ID
Authors

Ursem, Carling, Van Loon, Katherine, Venook, Alan

Abstract

In 2015, ramucirumab and TAS-102 became the 10th and 11th drugs approved by the Food and Drug administration for the treatment of patients with colorectal cancer, not counting leucovorin, and yet only 3 agents, 5-fluorouracil, capecitabine, and oxaliplatin, have proven benefit in adjuvant treatment. In fact, there have been no additions (and 1 subtraction levamisole) to our arsenal of therapies for patients with stages II and III colon cancer for more than a decade. How did we get here? Are we stuck? And how do we move forward?

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 14%
Unknown 6 86%

Demographic breakdown

Readers by professional status Count As %
Student > Master 2 29%
Student > Ph. D. Student 2 29%
Researcher 1 14%
Professor > Associate Professor 1 14%
Unspecified 1 14%
Other 0 0%
Readers by discipline Count As %
Unspecified 2 29%
Medicine and Dentistry 2 29%
Nursing and Health Professions 1 14%
Decision Sciences 1 14%
Immunology and Microbiology 1 14%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 July 2016.
All research outputs
#6,067,462
of 8,002,013 outputs
Outputs from Cancer Journal
#255
of 452 outputs
Outputs of similar age
#182,680
of 260,071 outputs
Outputs of similar age from Cancer Journal
#4
of 4 outputs
Altmetric has tracked 8,002,013 research outputs across all sources so far. This one is in the 13th percentile – i.e., 13% of other outputs scored the same or lower than it.
So far Altmetric has tracked 452 research outputs from this source. They receive a mean Attention Score of 2.3. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,071 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.